14-day Premium Trial Subscription Sign Up For FreeGet Free

When Should You SELL Your Stocks? Click to watch.

$3.35 (0.60%)

Volume: 1.994M

Closed: May 19, 2022

Hollow Logo Score: -3.194

bluebird bio Stock Forecast

BUY SELL NASDAQ:BLUE
$3.35 (0.60%)

Volume: 1.994M

Closed: May 19, 2022

Score Hollow Logo -3.194

bluebird bio Stock Forecast NASDAQ:BLUE

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-05-17 -10.45% Morgan Stanley $5.00 $3.00 Maintains Underweight
2022-05-10 -10.45% Barclays $4.00 $3.00 Maintains Underweight
2022-04-06 138.81% SVB Leerink $10.00 $8.00 Maintains Market Perform
2022-04-06 - Cowen & Co. - Downgrades Outperform Market Perform
2022-03-08 138.81% Wells Fargo $12.00 $8.00 Maintains Equal-Weight
2022-03-07 49.25% Morgan Stanley $6.00 $5.00 Maintains Underweight
2022-03-07 19.4% Barclays $13.00 $4.00 Downgrades Equal-Weight Underweight
2022-03-07 198.51% SVB Leerink $11.00 $10.00 Maintains Market Perform
2022-01-06 198.51% Morgan Stanley $11.00 $10.00 Maintains Underweight
2021-11-08 228.36% Morgan Stanley $11.00 Downgrades Equal-Weight Underweight
2021-11-08 198.51% Goldman Sachs $23.00 $10.00 Downgrades Neutral Sell
2021-11-08 288.06% Barclays $20.00 $13.00 Maintains Equal-Weight
2021-09-22 586.57% Mizuho $29.00 $23.00 Maintains Buy
2021-08-10 646.27% Wells Fargo $60.00 $25.00 Downgrades Overweight Equal-Weight
2021-08-10 497.01% Canaccord Genuity $86.00 $20.00 Downgrades Buy Hold
2021-08-10 586.57% Goldman Sachs $63.00 $23.00 Downgrades Buy Neutral
2021-07-16 944.78% Morgan Stanley $36.00 $35.00 Maintains Equal-Weight
2021-07-01 944.78% Berenberg $35.00 Downgrades Buy Hold
2021-04-19 974.63% Morgan Stanley $45.00 $36.00 Maintains Equal-Weight
2021-03-29 2049.25% SVB Leerink $69.00 $72.00 Maintains Outperform
2021-03-10 1959.7% Mizuho $34.00 $69.00 Upgrades Neutral Buy
2021-03-02 1243.28% Morgan Stanley $50.00 $45.00 Maintains Equal-Weight
2021-02-17 1064.18% JP Morgan $76.00 $39.00 Downgrades Overweight Neutral
2020-11-11 1810.45% Berenberg $64.00 Initiates Coverage On Buy
2020-11-11 1392.54% Morgan Stanley $68.00 $50.00 Maintains Equal-Weight
2020-11-05 1571.64% BMO Capital $56.00 Downgrades Outperform Market Perform
2020-11-05 1541.79% Piper Sandler $70.00 $55.00 Maintains Neutral
2020-11-05 2317.91% B of A Securities $100.00 $81.00 Maintains Buy
2020-11-05 2855.22% SVB Leerink $133.00 $99.00 Maintains Outperform
2020-10-20 3571.64% Mizuho $123.00 Initiates Coverage On Buy
2020-08-10 1929.85% Morgan Stanley $73.00 $68.00 Maintains Equal-Weight
2020-08-06 2317.91% Wedbush $89.00 $81.00 Maintains Outperform
2020-08-06 3123.88% BMO Capital $112.00 $108.00 Maintains Outperform
2020-07-13 2885.07% B of A Securities $104.00 $100.00 Maintains Buy
2020-06-12 3870.15% SVB Leerink $129.00 $133.00 Maintains Outperform
2020-05-28 2079.1% Morgan Stanley $69.00 $73.00 Maintains Equal-Weight
2020-05-28 3750.75% SVB Leerink $125.00 $129.00 Maintains Outperform
2020-05-13 2885.07% RBC Capital $100.00 Initiates Coverage On Outperform
2020-05-12 3243.28% BMO Capital $107.00 $112.00 Maintains Outperform
2020-04-15 1959.7% Morgan Stanley $92.00 $69.00 Maintains Equal-Weight
2020-03-27 1989.55% Stifel $94.00 $70.00 Upgrades Hold Buy
2020-02-26 2646.27% Morgan Stanley $100.00 $92.00 Maintains Equal-Weight
2020-02-19 2705.97% Stifel $96.00 $94.00 Maintains Hold
2020-02-03 2885.07% Evercore ISI Group $86.00 $100.00 Upgrades In-Line Outperform
2019-12-13 3929.85% Oppenheimer $135.00 Upgrades Perform Outperform
2019-12-09 4676.12% Wells Fargo $242.00 $160.00 Maintains Overweight
2019-11-26 3452.24% SVB Leerink $119.00 Upgrades Market Perform Outperform
2019-11-19 2467.16% Evercore ISI Group $86.00 Downgrades Outperform In-Line
2019-11-04 - Wedbush - Upgrades Neutral Outperform
2019-11-01 2885.07% Morgan Stanley $104.00 $100.00 Maintains Equal-Weight
2019-11-01 2437.31% Piper Sandler $120.00 $85.00 Maintains Neutral
2019-10-11 3004.48% Morgan Stanley $136.00 $104.00 Maintains Equal-Weight
2019-10-01 3153.73% Stifel $109.00 Initiates Coverage On Hold
2019-08-12 - William Blair - Downgrades Outperform Market Perform
2019-08-06 3959.7% Morgan Stanley $143.00 $136.00 Maintains Equal-Weight
2019-06-18 4676.12% Maxim Group $160.00 Upgrades Hold Buy
2019-06-17 4765.67% BMO Capital $191.00 $163.00 Maintains Outperform
2019-05-15 3810.45% Wedbush $166.00 $131.00 Downgrades Outperform Neutral

BLUE Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -35.11% during the next 3 months and, with a 90% probability hold a price between $1.94 and $2.64 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2022-05-23 $2.96 $3.50 $4.04
2022-05-24 $2.92 $3.46 $4.00
2022-05-25 $2.88 $3.43 $3.97
2022-05-26 $2.85 $3.39 $3.93
2022-05-27 $2.81 $3.35 $3.89
2022-05-31 $2.78 $3.32 $3.86
2022-06-01 $2.74 $3.28 $3.82
2022-06-02 $2.70 $3.24 $3.78
2022-06-03 $2.67 $3.21 $3.75
2022-06-06 $2.63 $3.17 $3.71
2022-06-07 $2.60 $3.14 $3.68
2022-06-08 $2.56 $3.10 $3.64
2022-06-09 $2.52 $3.06 $3.60
2022-06-10 $2.49 $3.03 $3.57
2022-06-13 $2.45 $2.99 $3.53
2022-06-14 $2.41 $2.96 $3.50
2022-06-15 $2.38 $2.92 $3.46
2022-06-16 $2.34 $2.88 $3.42
2022-06-17 $2.31 $2.85 $3.39
2022-06-21 $2.27 $2.81 $3.35
2022-06-22 $2.23 $2.77 $3.31
2022-06-23 $2.20 $2.74 $3.28
2022-06-24 $2.16 $2.70 $3.24
2022-06-27 $2.13 $2.67 $3.21
2022-06-28 $2.09 $2.63 $3.17
2022-06-29 $2.05 $2.59 $3.13
2022-06-30 $2.02 $2.56 $3.10
2022-07-01 $1.98 $2.52 $3.06
2022-07-05 $1.95 $2.49 $3.03
2022-07-06 $1.91 $2.45 $2.99

About bluebird bio

bluebird bio bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its product candidates include Lenti-D, which is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell di... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!
.

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT